Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 9, 2009, Pages 3330-3335

  Guillonneau, Carole ^a   Mintern, Justine D ^a   Hubert, François Xavier ^b   Hurt, Aeron C ^c   Besra, Gurdyal S ^d   Porcelli, Steven ^e   Barr, Ian G ^c   Doherty, Peter C ^a,f   Godfrey, Dale I ^a   Turner, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Institute of Medical Research   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adjuvant; T cell memory; Vaccine; Viral immunity

Indexed keywords

GLYCOLIPID ALPHA GALACTOSYLCERAMIDE; INDOLEAMINE 2,3 DIOXYGENASE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 62549116236     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813309106     Document Type: Article

References (38)

1. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61:94-99.
2. Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science 302:1519-1522.
3. Bender BS, Croghan T, Zhang L, Small PA, Jr (1992) Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175:1143-1145.
4. Doherty PC, Riberdy JM, Belz GT (2000) Quantitative analysis of the CD8+ T-cell response to readily eliminated and persistent viruses. Philos Trans R Soc Lond B Biol Sci 355:1093-1101.
5. Doherty PC, Kelso A (2008) Toward a broadly protective influenza vaccine. J Clin Invest 118:3273-3275.
6. Lee LY, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118:3478-3490.
7. Doherty PC, et al. (1997) Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159:105-117.
8. Deliyannis G, et al. (1998) Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16:2058-2068.
9. Singh M, O'Hagan D (1999) Advances in vaccine adjuvants. Nat Biotechnol 17:1075-1081.
10. Kawano T, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:1626-1629.
11. Hong S, et al. (1999) Lipid antigen presentation in the immune system: Lessons learned from CD1d knockout mice. Immunol Rev 169:31-44.
12. Kronenberg M (2005) Toward an understanding of NKT cell biology: Progress and paradoxes. Annu Rev Immunol 23:877-900.
13. Godfrey DI, Kronenberg M (2004) Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379-1388.
14. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297-336.
15. Galli G, et al. (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104:3984-3989.
16. Ko SY, et al. (2005) alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175:3309-3317.
17. Youn HJ, et al. (2007) A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25:5189-5198.
18. Ho LP, et al. (2008) Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol 38:1913-1922.
19. Renfrey S, Watts A (1994) Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12:747-752.
20. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: Function, generation, and maintenance. Ann Rev Immun 22:745-763.
21. Flynn KJ, et al. (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8:683-691.
22. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198:267-279.
23. Wilson NS, et al. (2006) Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 7:165-172.
24. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nature Rev 4:762-774.
25. Fallarini S, Paoletti T, Panza L, Lombardi G (2008) Alpha- galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells. Biochem Pharmacol 76:738-750.
26. Kaech SM, Hemby S, Kersh E, Ahmed R (2002) Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851.
27. Gonzalez-Aseguinolaza G, et al. (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195:617-624.
28. Chung Y, Chang WS, Kim S, Kang CY (2004) NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 34:2471-2479.
29. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC (1994) Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 369:652-654.
30. Kitamura H, et al. (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189:1121-1128.
31. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199:1607-1618.
32. Fallarino F, et al. (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069-1077.
33. Akbari O, et al. (2003) Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 9:582-588.
34. Badovinac VP, Harty JT (2006) Programming, demarcating, and manipulating CD8+ T-cell memory. Immunol Rev 211:67-80.
35. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT (2005) Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11:748-756.
36. Uldrich AP, et al. (2005) NKT cell stimulation with glycolipid antigen in vivo: Costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175:3092-3101.
37. Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R (2002) Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol 169:3760-3770.
38. Uyttenhove C, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274.